Dr. Reddy's Laboratories acquires UCB portfolio RA treatments to reach $9.3 billion in U.S. by 2020 Teva’s ProAir RespiClick granted FDA approval Amneal to acquire Actavis Australia’s generics business AstraZeneca launches Movantik Teva to strengthen CNS portfolio with Auspex acquisition At the scene of NACDS RxIMPACT Day FDA revisits label changes with public meeting Actavis-Allergan merger complete Generic or brand-name prescription drugs? A Harris Poll examines Americans' preference First Previous 137 138 139 140 141 Next Last